Portland, OR -- (SBWIRE) -- 08/23/2017 -- The major factors that fuel the growth of the Viral Vectors and Plasmid DNA Manufacturing Market include rise in number of candidates of gene therapy combined with their swift development through the numerous phases of clinical progression, ability of the vectors to express therapeutic genes efficiently, and nonpathogenic nature of vectors.

However, possible insertional mutagenesis and high cost of gene therapies impede the market growth. Technological advancements to alleviate the challenges caused by the traditional methods of vector production provide broad range of opportunities for the manufacturers in this market.

The global viral vector and plasmid DNA manufacturing market is segmented on the basis of product, application, and geography. Based on product, the market is divided into plasmid DNA, viral vectors, and nonviral vectors. Applications covered in this study include cancers, inherited disorders, viral infections, and others. Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key companies profiled in this report include Spark Therapeutics, Inc., Genzyme Corporation, Aldevron, Kaneka Eurogentec S.A., Biovian, Brammer Bio, Cobra Biologics, FinVector Vision Therapies, Oxford Gene Technology, and Vigene Biosciences Inc.

Key Benefits

- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It presents a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market by type assists to understand the regional trends.
- Key players and their strategies have been analyzed to understand the competitive outlook of the market.

Early buyers will receive 20% customization on this report
Get PDF Brochure of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/2681